Hepatic Epithelioid Hemangioendothelioma and Adult Liver Transplantation: Proposal for a Prognostic Score Based on the Analysis of the ELTR-ELITA Registry
Language English Country United States Media print
Document type Journal Article, Multicenter Study
PubMed
28212256
DOI
10.1097/tp.0000000000001603
PII: 00007890-201703000-00021
Knihovny.cz E-resources
- MeSH
- Algorithms MeSH
- Time Factors MeSH
- Adult MeSH
- Hemangioendothelioma, Epithelioid diagnosis mortality surgery MeSH
- Risk Assessment MeSH
- Neoplasm Invasiveness MeSH
- Kaplan-Meier Estimate MeSH
- Middle Aged MeSH
- Humans MeSH
- Neoplasm Recurrence, Local MeSH
- Lymphatic Metastasis MeSH
- Decision Support Techniques * MeSH
- Multivariate Analysis MeSH
- Liver Neoplasms diagnosis mortality surgery MeSH
- Neoadjuvant Therapy MeSH
- Predictive Value of Tests MeSH
- Disease-Free Survival MeSH
- Graft Survival MeSH
- Proportional Hazards Models MeSH
- Registries MeSH
- Retrospective Studies MeSH
- Risk Factors MeSH
- Waiting Lists MeSH
- Propensity Score MeSH
- Liver Transplantation * adverse effects mortality MeSH
- Patient Selection MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Geographicals
- Europe MeSH
BACKGROUND: Hepatic epithelioid hemangioendothelioma (HEHE) is a rare vascular tumor which has an intermediate aggressive behavior. Although the value of liver transplantation (LT) is well established, its place in the management of HEHE is still unclear. The aim of this study is to confirm, based on a very large patient cohort, the value of LT in the management of HEHE and to identify risk factors for post-LT recurrence. METHODS: The outcome of 149 transplant recipients with HEHE recorded in the European Liver Transplant Registry during the period November 1984 to May 2014 was analyzed. Median post-LT follow-up was 7.6 years (interquartile range, 2.8-14.4). RESULTS: Cox regression analysis showed that macrovascular invasion (hazard ratio [HR], 4.8; P < 0.001), pre-LT waiting time of 120 days or less (HR, 2.6; P = 0.01) and hilar lymph node invasion (HR = 2.2; P = 0.03), but not pre-LT extrahepatic disease, were significant risk factors for recurrence. These findings, which were also confirmed in a propensity score analysis, allowed the development of a HEHE-LT score enabling stratification of patients in relation to their risk of tumor recurrence. Patients with a score of 2 or less had a much better 5-year disease-free survival compared to those having a score of 6 or higher (93.9% vs 38.5%; P < 0.001). CONCLUSIONS: The analysis of this (largest in the world) HEHE adult liver recipient cohort clearly confirms the value of LT in the treatment of this rare disorder and also permits identification of patients at risk of posttransplant recurrence. Posttransplant follow-up should take the HEHE-LT score into account. Extrahepatic disease localization is reconfirmed not to be a contraindication for LT.
References provided by Crossref.org